Research Reports

Key takeaways

Total revenue was $5.9 million, essentially flat year-over-year, due to lower traceability onboarding after the FSMA 204 deadline extension.

Operating expense decreased 12% to $3.6 million, driving a 24% increase in operating income to $2.3 million.

GAAP net income to common shareholders rose 4% to $2.0 million; diluted EPS was $0.10 per share.

The Board declared a quarterly dividend of $0.02 per share, paid on May 15, 2026; company repurchased 55,262 common shares for $550,000.

Ended the quarter with $26.4 million cash, no bank debt, and invested $3.0 million in a note receivable (SPAR Group).

Filed two patent applications for Touchless Traceability; solution deployed at a leading grocer and a Southern wholesaler.

Full analysis

ReposiTrak's third fiscal quarter results reflect a revenue plateau due to the FSMA 204 deadline shift, which pulled forward traceability onboarding into the prior-year period. Despite flat top-line, operating income expanded 24% as cost of revenue and SG&A declined, demonstrating operating leverage. Net income to common shareholders rose 4% on lower preferred dividends. The company maintained strong cash generation, with $5.9 million in operating cash flow year-to-date, and ended the quarter with $26.4 million in cash and no debt. Capital returns continued with a $0.02 quarterly dividend and common share repurchases. Strategically, ReposiTrak filed two patents for its Touchless Traceability solution, now deployed at two major customers, and formed a collaboration with SPAR Group to offer in-store execution services. These actions aim to deepen its competitive moat and extend platform capabilities beyond diagnostics into remediation.

TRAK · ReposiTrak, Inc.

Summary

Key takeaways

Full analysis